#AIEye
#Podcast Episode 560: #Stocks discussed: (NYSE: $YEXT) (NasdaqGS: $KRBP)
#artificialintelligence
Yext
Launches Support Answers, and Kiromic
BioPharma Submits #AI-Derived IND Trial to FDA
Business
Use of #AI Valued at $1.8T by 2027
Point Roberts WA, Vancouver BC – May 24, 2021 – Investorideas.com (www.investorideas.com), a global investor news source covering
Artificial Intelligence (AI) brings you today’s edition of The
AI Eye- watching stock news, deal
tracker and advancements in artificial intelligence
Listen
to today’s podcast:
https://www.investorideas.com/Audio/Podcasts/2021/052421-AI-Eye.mp3
Read
this in full at https://www.investorideas.com/news/2021/artificial-intelligence/05241YEXT-KRBP.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and advancements
in artificial intelligence
Stocks
discussed: (NYSE:YEXT) (NasdaqGS:KRBP)
AI search company Yext, Inc. (NYSE:YEXT)
has announced the launch of Support Answers, “a
suite of enterprise search solutions built for customer support teams.” This
will employ modern, AI-powered solutions to provide answers to “a business's
FAQs, product manuals, help articles, and more.” Marc Ferrentino, Chief
Strategy Officer at Yext, said:
"Customers
have consistently expressed their aversion to contacting customer support, but
for the longest time, businesses have not had the technology powerful enough
for them to resolve their issues independently. Today, that changes with the
launch of Support Answers, which leverages our platform's multiple search
algorithms to interpret people's intent and deliver contextually relevant,
direct answers in a way that meets consumers' needs and expectations, and saves
a business time and money."
Kiromic BioPharma, Inc. (NasdaqGS:KRBP) has submitted a novel Investigational New Drug
(IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical
trial, derived from the company’s proprietary artificial intelligence neural
network platform (Diamond AI), that “has the potential to be a universal CAR
T-Cell therapy for any solid malignancy that expresses the biomarker
Iso-mesothelin, with higher efficacy, higher safety, as well as lower
manufacturing and distribution costs.” Maurizio Chiriva-Internati, CEO of
Kiromic, explained:
Kiromic
is in a unique position because its bioinformatic engine combines CancerDiff, a
data-mining tool for the identification of tumor-preferred isoforms, with
Diamond, an AI-driven immunogenic peptide identification system.
This
combination allows Kiromic to identify targetable sections of a tumor isoform
(peptides) that are a unique signature of cancer cells.
The
advantage of Kiromic’s system is two-fold: 1) it saves time and money because
it allows the prioritization of tumor-selective targets, and 2) it maximizes the
likelihood of identifying targets that are safe by increasing the targeting
specificity.
Business
Use of AI Valued at $1.8T by 2027
A report published by Research and Markets analyzing the global
Artificial General Intelligence market, finds that “the productivity gain
potential for business use of AI represents approximately $1.8T in economic
value by 2027.” A further excerpt from the report’s description indicates that
this:
“…will
be nine times more with the use of general-purpose AI solutions market as
compared to today's silo AI approach. Productivity gains will be achieved by
transactions conducted by AI autonomous agents or “bots”. It is estimated that
more than 8% of the global economic activity in 2027 will be done autonomously
by some kind of AI solution whereas this amounts to less than one percent
today. This represents a dramatic rise in the use of AI for enterprise,
industrial, and government automation.”
The report also projects variously that the embedded AI
in building infrastructure and equipment will reach $18.1 globally by 2026, the
general-purpose AI market will reach $4.25B globally by 2026 for enterprise
apps and solutions, the global market for general-purpose AI support of big
data and prescriptive analytics will reach $1.35B, and that over 35% of
enterprise value will be directly or indirectly attributable to general-purpose
AI solutions by 2027.
Sam Mowers, Investorideas.com
Read and hear other editions of the
AI Eye
For a list of artificial intelligence
stocks on Investorideas.com visit here
Investors can trade these stocks and
other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
publishes breaking stock news, third
party stock research , guest posts and original
articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast , Cleantech and Climate
Change , Exploring Mining , Betting on Gaming Stocks
Podcast and the AI Eye Podcast
The Investorideas.com podcasts are also
available on iTunes ( Apple Podcasts) ,
Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google
Play Music and most audio platforms available.
Visit the Podcast page at
Investorideas.com:
https://www.investorideas.com/Audio/
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com Global investors
must adhere to regulations of each country. Please read Investorideas.com
privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Follow us on
Twitter https://twitter.com/Investorideas
Follow us on
Facebook https://www.facebook.com/Investorideas
Follow us on
YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor
Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Technology stock investor
ideas - news, articles, podcasts and stock directories
No comments:
Post a Comment